Whether the miR-125b-5p/TNFAIP3 axis can be used as a therapeutic approach for increasing DLBCL sensitivity to anti-CD20 antibodies requires further investigations. This evidence concerns the gene TNFAIP3 and diffuse large B-cell lymphoma.